Neoadjuvant therapy for non-metastatic pancreatic ductal adenocarcinoma

Seminars in Oncology

Volumn 42, Issue 1, 2015, Pages 86-97

  Winner, Megan ^a   Goff, Stephanie L ^b   Chabot, John A ^c  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Department of Surgery ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; MITOMYCIN; OXALIPLATIN; PACLITAXEL; TEGAFUR;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; HISTOPATHOLOGY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; SURGICAL TECHNIQUE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CARCINOMA, PANCREATIC DUCTAL; PANCREATIC NEOPLASMS;

CARCINOMA, PANCREATIC DUCTAL; CHEMOTHERAPY, ADJUVANT; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS;

EID: 84923450708     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2014.12.008     Document Type: Review

References (93)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA 64 2014 9 29
2. R.E. Royal, R.A. Wolff, and C.H. Crane Pancreatic cancer. Devita, Hellman, and Rosenberg's Cancer. 8 ed 2008 Lippincott Williams & Wilkins Philadelphia, PA
3. M.A. Tempero, J.P. Arnoletti, and S.W. Behrman Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN guidelines J Natl Compr Cancer Network 10 2012 703 713
4. T.A. Sohn, C.J. Yeo, and J.L. Cameron Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators J Gastrointest Surg 4 6 2000 567 579
5. K.Y. Bilimoria, D.J. Bentrem, K.D. Lillemoe, M.S. Talamonti, and C.Y. Ko Assessment of pancreatic cancer care in the United States based on formally developed quality indicators J Natl Cancer Inst 101 12 2009 848 859
6. H. Oettle, S. Post, and P. Neuhaus Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial JAMA 297 3 2007 267 277
7. J.H. Klinkenbijl, J. Jeekel, and T. Sahmoud Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group Ann Surg 230 6 1999 776 782
8. J.P. Neoptolemos, D.D. Stocken, and H. Friess A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N Engl J Med 350 12 2004 1200 1210
9. G.R. Varadhachary, E.P. Tamm, and J.L. Abbruzzese Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy Ann Surg Oncol 13 8 Aug 2006 1035 1046
10. A.J. Weiss, and L. Jackson The effect of 5-fluorouracil upon carcinomas of the gastrointestinal tract and related organs Am J Gastroenterol 35 1961 138 146
11. M.H. Kaiser, and S.S. Ellenberg Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection Arch Surg 120 8 1985 899 903
12. Group GTS. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group Cancer 59 12 1987 2006 2010
13. D.B. Evans Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region Ann Surg 232 5 2000 727
14. M.C. Garofalo, W.F. Regine, and M.T. Tan On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer Ann Surg 244 2 2006 332 333
15. S. Heinrich, B. Pestalozzi, and M. Lesurtel Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study) BMC Cancer 11 2011 346
16. E.S. Casper, M.R. Green, and D.P. Kelsen Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas Invest New Drugs 12 1 1994 29 34
17. W.F. Regine, K.A. Winter, and R. Abrams Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial Ann Surg Oncol 18 5 2011 1319 1326
18. J.P. Neoptolemos, D.D. Stocken, and C. Bassi Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial JAMA 304 10 2010 1073 1081
19. H.A. Burris III, M.J. Moore, and J. Andersen Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 6 1997 2403 2413
20. F.R. Spitz, J.L. Abbruzzese, and J.E. Lee Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas J Clin Oncol 15 3 1997 928 937
21. C.J. Yeo, J.L. Cameron, and T.A. Sohn Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes Ann Surg 226 3 1997 248 257
22. T.A. Aloia, J.E. Lee, and J.N. Vauthey Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? J Am Coll Surg 204 3 2007 347 355
23. K.Y. Bilimoria, D.J. Bentrem, and C.Y. Ko Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume Cancer 110 6 2007 1227 1234
24. D.B. Evans, D.R. Byrd, and P.F. Mansfield Preoperative chemoradiotherapy for adenocarcinoma of the pancreas. Rationale and technique Am J Clin Oncol 14 4 1991 359 364
25. J.M. Jessup, G. Steele Jr., and R.J. Mayer Neoadjuvant therapy for unresectable pancreatic adenocarcinoma Arch Surg 128 5 1993 559 564
26. R. Krempien, M.W. Muenter, W. Harms, and J. Debus Neoadjuvant chemoradiation in patients with pancreatic adenocarcinoma HPB 8 1 2006 22 28
27. J.D. Allendorf, M. Lauerman, and A. Bill Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival J Gastrointest Surg 12 1 2008 91 100
28. M. Wagner, C. Redaelli, M. Lietz, C.A. Seiler, H. Friess, and M.W. Buchler Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma Br J Surg 91 5 2004 586 594
29. J.A. Glant, J.A. Waters, and M.G. House Does the interval from imaging to operation affect the rate of unanticipated metastasis encountered during operation for pancreatic adenocarcinoma? Surgery 150 4 2011 607 616
30. P.J. Kneuertz, S.C. Cunningham, and J.L. Cameron Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience J Gastrointest Surg 15 11 2011 1917 1927
31. L. Barbier, O. Turrini, E. Gregoire, F. Viret, Y.P. Le Treut, and J.R. Delpero Pancreatic head resectable adenocarcinoma: preoperative chemoradiation improves local control but does not affect survival HPB 13 1 2011 64 69
32. A. Artinyan, D.A. Anaya, S. McKenzie, J.D. Ellenhorn, and J. Kim Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma Cancer 117 10 2011 2044 2049
33. C.W. Tzeng, H.S. Tran Cao, and J.E. Lee Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival J Gastrointest Surg 18 1 2014 16 24
34. M.H. Katz, J.B. Fleming, and P. Bhosale Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators Cancer 118 23 2012 5749 5756
35. I. Epelboym, J. Dinorcia, and M. Winner Neoadjuvant therapy and vascular resection during pancreaticoduodenectomy: shifting the survival curve for patients with locally advanced pancreatic cancer World J Surg Dec 5, 2013
36. A.L. Warshaw, K.D. Lillemoe, and C. Fernandez-del Castillo Pancreatic surgery for adenocarcinoma Curr Opin Gastroenterol 28 5 2012 488 493
37. F. Leone, M. Gatti, and P. Massucco Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience Cancer 119 2 2013 277 284
38. G. Barugola, S. Partelli, and S. Crippa Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy Am J Surg 203 2 2012 132 139
39. D.B. Evans, T.A. Rich, and D.R. Byrd Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas Arch Surg 127 11 1992 1335 1339
40. Q. Zhao, A. Rashid, and Y. Gong Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis Ann Diagn Pathol 16 1 2012 29 37
41. J.S. Estrella, A. Rashid, and J.B. Fleming Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation Cancer 118 1 2012 268 277
42. M. Sho, T. Akahori, and T. Tanaka Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer J Hepatobiliary Pancreatic Sci 20 2 2013 197 205
43. T.Y. Cheng, K. Sheth, and R.R. White Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy Ann Surg Oncol 13 1 2006 66 74
44. H. Takahashi, H. Ogawa, and H. Ohigashi Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma Surgery 150 3 2011 547 556
45. S. Gillen, T. Schuster, C. Meyer Zum Buschenfelde, H. Friess, and J. Kleeff Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages PLoS Med 7 4 2010 e1000267
46. M.M. Assifi, X. Lu, G. Eibl, H.A. Reber, G. Li, and O.J. Hines Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials Surgery 150 3 2011 466 473
47. T.C. Chua, and A. Saxena Preoperative chemoradiation followed by surgical resection for resectable pancreatic cancer: a review of current results Surg Oncol 20 4 2011 e161 e168
48. N. Maisey, I. Chau, and D. Cunningham Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer J Clin Oncol 20 14 2002 3130 3136
49. M. Choi, S. Razzaque, and R. Kim Systemic therapy of advanced pancreatic cancer: has the landscape changed? Clin Adv Hematol Oncol 10 7 2012 442 451
50. J.F. Pingpank, J.P. Hoffman, and E.A. Ross Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas J Gastrointest Surg 5 2 2001 121 130
51. S.E. Greer, J.M. Pipas, and J.E. Sutton Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma J Am Coll Surg 206 3 2008 451 457
52. H.J. Kim, K. Czischke, M.F. Brennan, and K.C. Conlon Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer? J Gastrointest Surg 6 5 2002 763 769
53. H. Takahashi, H. Ohigashi, and K. Gotoh Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer Ann Surg 258 6 2013 1040 1050
54. T.M. Breslin, K.R. Hess, and D.B. Harbison Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration Ann Surg Oncol 8 2 2001 123 132
55. P.J. Hosein, J. Macintyre, and C. Kawamura A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma BMC Cancer 12 2012 199
56. P.W. Pisters, J.L. Abbruzzese, and N.A. Janjan Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma J Clin Oncol 16 12 1998 3843 3850
57. J.P. Hoffman, S. Lipsitz, T. Pisansky, J.L. Weese, L. Solin, and A.B. Benson III Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study J Clin Oncol 16 1 1998 317 323
58. R.R. White, H.I. Hurwitz, and M.A. Morse Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas Ann Surg Oncol 8 10 2001 758 765
59. P.W. Pisters, R.A. Wolff, and N.A. Janjan Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome J Clin Oncol 20 10 2002 2537 2544
60. F.A. Calvo, R. Matute, and J.L. Garcia-Sabrido Neoadjuvant chemoradiation with tegafur in cancer of the pancreas: initial analysis of clinical tolerance and outcome Am J Clin Oncol 27 4 2004 343 349
61. M.S. Talamonti, W. Small Jr., and M.F. Mulcahy A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma Ann Surg Oncol 13 2 2006 150 158
62. D.H. Palmer, D.D. Stocken, and H. Hewitt A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin Ann Surg Oncol 14 7 2007 2088 2096
63. P. Vento, H. Mustonen, T. Joensuu, P. Karkkainen, E. Kivilaakso, and T. Kiviluoto Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer World J Gastroenterol 13 21 2007 2945 2951
64. D.B. Evans, G.R. Varadhachary, and C.H. Crane Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head J Clin Oncol 26 21 2008 3496 3502
65. S. Heinrich, M. Schafer, and A. Weber Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial Ann Surg 248 6 2008 1014 1022
66. R. Le Scodan, F. Mornex, and C. Partensky Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial Am J Clin Oncol 31 6 2008 545 552
67. S. Takai, S. Satoi, and H. Yanagimoto Neoadjuvant chemoradiation in patients with potentially resectable pancreatic cancer Pancreas 36 1 2008 e26 e32
68. G.R. Varadhachary, R.A. Wolff, and C.H. Crane Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head J Clin Oncol 26 21 2008 3487 3495
69. O. Turrini, F. Viret, and L. Moureau-Zabotto Neoadjuvant 5 fluorouracil-cisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: a ten-year single institution experience Oncology 76 6 2009 413 419
70. O. Turrini, M. Ychou, and L. Moureau-Zabotto Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response Eur J Surg Oncol 36 10 2010 987 992
71. K.T. Papalezova, D.S. Tyler, and D.G. Blazer III Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? J Surg Oncol 106 1 2012 111 118
72. V.K. Mehta, G. Fisher, and J.A. Ford Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas J Gastrointest Surg 5 1 2001 27 35
73. M.H. Katz, P.W. Pisters, and D.B. Evans Borderline resectable pancreatic cancer: the importance of this emerging stage of disease J Am Coll Surg 206 5 2008 833 846
74. R.J. McClaine, A.M. Lowy, J.J. Sussman, N. Schmulewitz, D.L. Grisell, and S.A. Ahmad Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer HPB 12 1 2010 73 79
75. J.B. Stokes, N.J. Nolan, and E.B. Stelow Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer Ann Surg Oncol 18 3 2011 619 627
76. M. Patel, S. Hoffe, and M. Malafa Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer J Surg Oncol 104 2 2011 155 161
77. J.B. Rose, F.G. Rocha, and A. Alseidi Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival Ann Surg Oncol 2014 1 8
78. K.K. Christians, S. Tsai, and A. Mahmoud Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist Feb 25, 2014
79. L. Coia, J. Hoffman, and R. Scher Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum Int J Radiat Oncol Biol Phys 30 1 1994 161 167
80. A.G. Kamthan, J.C. Morris, and J. Dalton Combined modality therapy for stage II and stage III pancreatic carcinoma J Clin Oncol 15 8 1997 2920 2927
81. E. Bajetta, M. Di Bartolomeo, and S.C. Stani Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study Int J Radiat Oncol Biol Phys 45 2 1999 285 289
82. H. Snady, H. Bruckner, A. Cooperman, J. Paradiso, and L. Kiefer Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma An outcomes trial. Cancer 89 2 2000 314 327
83. H.J. Wanebo, A.S. Glicksman, and M.P. Vezeridis Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer Arch Surg 135 1 2000 81 87
84. C.H. Crane, J.L. Abbruzzese, and D.B. Evans Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 52 5 2002 1293 1302
85. V. Moutardier, M. Giovannini, and B. Lelong A phase II single institutional experience with preoperative radiochemotherapy in pancreatic adenocarcinoma Eur J Surg Oncol 28 5 2002 531 539
86. J.B. Ammori, L.M. Colletti, and M.M. Zalupski Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas J Gastrointest Surg 7 6 2003 766 772
87. T.K. Joensuu, T. Kiviluoto, and P. Karkkainen Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer Int J Radiat Oncol Bio Phys 60 2 2004 444 452
88. R. Wilkowski, M. Thoma, R. Schauer, A. Wagner, and V. Heinemann Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer World J Surg 28 10 2004 1011 1018
89. A. Sa Cunha, A. Rault, and C. Laurent Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas J Am Coll Surg 201 3 2005 359 365
90. R. Wilkowski, M. Thoma, C. Bruns, A. Wagner, and V. Heinemann Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer JOP 7 4 2006 349 360
91. P.A. Lind, B. Isaksson, and M. Almstrom Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma Acta Oncol 47 3 2008 413 420
92. J.L. Marti, H.S. Hochster, S.P. Hiotis, B. Donahue, T. Ryan, and E. Newman Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer Ann Surg Oncol 15 12 2008 3521 3531
93. J. Landry, P.J. Catalano, and C. Staley Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma J Surg Oncol 101 7 2010 587 592